Recurrent Rectal Cancer Active Not Recruiting Phase 1 Trials for Alisertib (DB05220)

Also known as: Rectal cancer recurrent / Carcinoma rectum recurrent / Rectal carcinoma recurrent / Carcinoma of rectum recurrent

IndicationStatusPhase
DBCOND0028583 (Recurrent Rectal Cancer)Active Not Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01923337Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal CancerTreatment